BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 27742111)

  • 1. Response Assessment in Neuro-Oncology Criteria and Clinical Endpoints.
    Huang RY; Wen PY
    Magn Reson Imaging Clin N Am; 2016 Nov; 24(4):705-718. PubMed ID: 27742111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging Criteria in Neuro-oncology.
    Nowosielski M; Wen PY
    Semin Neurol; 2018 Feb; 38(1):24-31. PubMed ID: 29548049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response Assessment in Neuro-Oncology Clinical Trials.
    Wen PY; Chang SM; Van den Bent MJ; Vogelbaum MA; Macdonald DR; Lee EQ
    J Clin Oncol; 2017 Jul; 35(21):2439-2449. PubMed ID: 28640707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response Assessment in Pediatric Neuro-Oncology: Implementation and Expansion of the RANO Criteria in a Randomized Phase II Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas.
    Jaspan T; Morgan PS; Warmuth-Metz M; Sanchez Aliaga E; Warren D; Calmon R; Grill J; Hargrave D; Garcia J; Zahlmann G
    AJNR Am J Neuroradiol; 2016 Sep; 37(9):1581-7. PubMed ID: 27127006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group.
    Vogelbaum MA; Jost S; Aghi MK; Heimberger AB; Sampson JH; Wen PY; Macdonald DR; Van den Bent MJ; Chang SM
    Neurosurgery; 2012 Jan; 70(1):234-43; discussion 243-4. PubMed ID: 21593697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updated Response Assessment in Neuro-Oncology (RANO) for Gliomas.
    Youssef G; Wen PY
    Curr Neurol Neurosci Rep; 2024 Feb; 24(2):17-25. PubMed ID: 38170429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults.
    Wen PY; van den Bent M; Youssef G; Cloughesy TF; Ellingson BM; Weller M; Galanis E; Barboriak DP; de Groot J; Gilbert MR; Huang R; Lassman AB; Mehta M; Molinaro AM; Preusser M; Rahman R; Shankar LK; Stupp R; Villanueva-Meyer JE; Wick W; Macdonald DR; Reardon DA; Vogelbaum MA; Chang SM
    J Clin Oncol; 2023 Nov; 41(33):5187-5199. PubMed ID: 37774317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Brain Tumor Response: RANO and Its Offspring.
    Eisele SC; Wen PY; Lee EQ
    Curr Treat Options Oncol; 2016 Jul; 17(7):35. PubMed ID: 27262709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classification of High-Grade Glioma into Tumor and Nontumor Components Using Support Vector Machine.
    Blumenthal DT; Artzi M; Liberman G; Bokstein F; Aizenstein O; Ben Bashat D
    AJNR Am J Neuroradiol; 2017 May; 38(5):908-914. PubMed ID: 28385884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pseudoprogression and pseudoresponse in the treatment of gliomas.
    Brandsma D; van den Bent MJ
    Curr Opin Neurol; 2009 Dec; 22(6):633-8. PubMed ID: 19770760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response Assessment in Neuro-Oncology Criteria for Gliomas: Practical Approach Using Conventional and Advanced Techniques.
    Leao DJ; Craig PG; Godoy LF; Leite CC; Policeni B
    AJNR Am J Neuroradiol; 2020 Jan; 41(1):10-20. PubMed ID: 31857322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response assessment criteria for brain metastases: proposal from the RANO group.
    Lin NU; Lee EQ; Aoyama H; Barani IJ; Barboriak DP; Baumert BG; Bendszus M; Brown PD; Camidge DR; Chang SM; Dancey J; de Vries EG; Gaspar LE; Harris GJ; Hodi FS; Kalkanis SN; Linskey ME; Macdonald DR; Margolin K; Mehta MP; Schiff D; Soffietti R; Suh JH; van den Bent MJ; Vogelbaum MA; Wen PY;
    Lancet Oncol; 2015 Jun; 16(6):e270-8. PubMed ID: 26065612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pros and cons of current brain tumor imaging.
    Ellingson BM; Wen PY; van den Bent MJ; Cloughesy TF
    Neuro Oncol; 2014 Oct; 16 Suppl 7(Suppl 7):vii2-11. PubMed ID: 25313235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
    Wen PY; Macdonald DR; Reardon DA; Cloughesy TF; Sorensen AG; Galanis E; Degroot J; Wick W; Gilbert MR; Lassman AB; Tsien C; Mikkelsen T; Wong ET; Chamberlain MC; Stupp R; Lamborn KR; Vogelbaum MA; van den Bent MJ; Chang SM
    J Clin Oncol; 2010 Apr; 28(11):1963-72. PubMed ID: 20231676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of Tumour Progression and Pseudoprogression in High-Grade Gliomas: a Systematic Review and Meta-Analysis.
    Abbasi AW; Westerlaan HE; Holtman GA; Aden KM; van Laar PJ; van der Hoorn A
    Clin Neuroradiol; 2018 Sep; 28(3):401-411. PubMed ID: 28466127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma.
    Youssef G; Rahman R; Bay C; Wang W; Lim-Fat MJ; Arnaout O; Bi WL; Cagney DN; Chang YS; Cloughesy TF; DeSalvo M; Ellingson BM; Flood TF; Gerstner ER; Gonzalez Castro LN; Guenette JP; Kim AE; Lee EQ; McFaline-Figueroa JR; Potter CA; Reardon DA; Huang RY; Wen PY
    J Clin Oncol; 2023 Jun; 41(17):3160-3171. PubMed ID: 37027809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.
    Nayak L; DeAngelis LM; Brandes AA; Peereboom DM; Galanis E; Lin NU; Soffietti R; Macdonald DR; Chamberlain M; Perry J; Jaeckle K; Mehta M; Stupp R; Muzikansky A; Pentsova E; Cloughesy T; Iwamoto FM; Tonn JC; Vogelbaum MA; Wen PY; van den Bent MJ; Reardon DA
    Neuro Oncol; 2017 May; 19(5):625-635. PubMed ID: 28453751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Updated response assessment criteria for high-grade glioma: beyond the MacDonald criteria.
    Sharma M; Juthani RG; Vogelbaum MA
    Chin Clin Oncol; 2017 Aug; 6(4):37. PubMed ID: 28841799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing available criteria for measuring brain metastasis response to immunotherapy.
    Qian JM; Mahajan A; Yu JB; Tsiouris AJ; Goldberg SB; Kluger HM; Chiang VLS
    J Neurooncol; 2017 May; 132(3):479-485. PubMed ID: 28275886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posttreatment Evaluation of Brain Gliomas.
    Dalesandro MF; Andre JB
    Neuroimaging Clin N Am; 2016 Nov; 26(4):581-599. PubMed ID: 27712795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.